The payments industry in Germany: Status and further developments or a triangle of scale, complexity and low fees
Journal of Payments Strategy & Systems · 01.09.2023 · 17 (3) · 323
DOI: 10.69554/iddl6676 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Payments Strategy & Systems, online erschienen am 01.09.2023. Verfasst von Niklas Bartelt und 1 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref).
Abstract (Originalsprache)
The German payments market is sizeable, handling almost one-quarter of the non-cash transactions conducted in the euro area, and benefiting from structurally lower cost levels. At the same time, it is characterised by a highly complex and intense competitive set. These two factors seem to result in low fee levels. The COVID-19 pandemic has accelerated structural change (and digital payments adoption) in a market with distinctive institutions and consumer preferences. This paper reviews both the key players shaping the overall payments market, as well as the characteristics of key payment solutions and situations. In doing so, the paper identifies and explains the idiosyncrasies of the German market, linking back to the aforementioned factors shaping the German payments market.
Zitieren
APA
Bartelt, N., & Wittig, R. (2023). The payments industry in Germany: Status and further developments or a triangle of scale, complexity and low fees. Journal of Payments Strategy & Systems, 17(3), 323. https://doi.org/10.69554/iddl6676
Vancouver
Bartelt N, Wittig R. The payments industry in Germany: Status and further developments or a triangle of scale, complexity and low fees. Journal of Payments Strategy & Systems. 2023;17(3):323. doi:10.69554/iddl6676
BibTeX
@article{Bartelt2023,
author = {Bartelt, Niklas and Wittig, Ronny},
title = {The payments industry in Germany: Status and further developments or a triangle of scale, complexity and low fees},
journal = {Journal of Payments Strategy & Systems},
year = {2023},
volume = {17},
number = {3},
pages = {323},
doi = {10.69554/iddl6676}
}
EUVIMED